A randomized, open-label study of prophylactic administration of PEGASYS [peginterferon alfa-2a] plus ribavirin [COPEGUS; Roche] after liver transplantation on hepatitis C recurrence in patients with hepatitis C.
Phase of Trial: Phase IV
Latest Information Update: 02 Apr 2018
At a glance
- Drugs Peginterferon alfa-2a; Ribavirin
- Indications Hepatitis C
- Focus Adverse reactions; Therapeutic Use
- Acronyms PHOENIX
- 30 Oct 2009 Results presented at the 60th Annual Meeting of the American Association for the Study of Liver Diseases.
- 02 Dec 2008 Status changed from active, no longer recruiting to completed.
- 19 Mar 2008 The expected completion date for this trial is now 1 Oct 2008, according to ClinicalTrials.gov.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History